Abstract
In 2022 the US government announced the Inflation Reduction Act (IRA), which included several provisions to lower Medicare patients’ prescription drug costs and reduce spending by the federal government. Starting in 2024, the IRA caps out-of-pocket spending for Medicare Part D enrollees by eliminating the 5% co-pay within the catastrophic threshold. Then, from 2025, the legislation adds a $2,000 hard cap on out-of-pocket spending, while mandating manufacturers to cover 20% of costs from catastrophic coverage. In this study, our aim is to compare the cost of Humira and CT-P17, Celltrion’s adalimumab biosimilar, by estimating the amount that each stakeholder would spend in 2024 and 2025 versus in 2023.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
